Halothane hepatitis: A double defect?
Leo Ranek – 1 May 1986 – We studied susceptibility to halothane hepatitis with an in vitro test that detects cell damage from electrophilic drug intermediates. Metabolites of phenytoin were generated by incubation of phenytoin with rat hepatic microsomes in the presence of the epoxide hydrolase inhibitor 1,1,1‐trichloropropene oxide (TCPO), which prevents the further metabolism of phenytoin to an inert metabolite.